Lord, Abbett & Co. LLC Ascendis Pharma A/S Transaction History

Lord, Abbett & Co. LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$63.77 - $76.28 $9.34 Million - $11.2 Million	-146,403 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$58.55 - $73.92 $3.41 Million - $4.31 Million	-58,304 Reduced 28.48%	146,403 $9.74 Million
Q1 2018 May 15, 2018	SELL	$38.98 - $68.04 $1.87 Million - $3.27 Million	-47,991 Reduced 18.99%	204,707 $13.4 Million
Q4 2017 Feb 14, 2018	SELL	$31.98 - $40.38 $190,440 - $240,462	-5,955 Reduced 2.3%	252,698 $10.1 Million
Q3 2017 Nov 14, 2017	BUY	$26.89 - $37.1 $6.96 Million - $9.6 Million	258,653	258,653 $9.38 Million

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.